Get the Stockscreener App
184.71
0.49%
0.90
Beigene Ltd Adr stock is traded at $184.71, with a volume of 331.61K.
It is up +0.49% in the last 24 hours and up +0.00% over the past month.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
See More
Previous Close:
$183.81
Open:
$184
24h Volume:
331.61K
Relative Volume:
0.91
Market Cap:
$19.68B
Revenue:
$3.32B
Net Income/Loss:
$-860.46M
P/E Ratio:
-22.20
EPS:
-8.32
Net Cash Flow:
$-1.04B
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
-4.70%
1Y Performance:
+19.09%
1-Day Range:
$183.91
$187.42
1-Week Range:
$183.91
$187.42
52-Week Range:
$126.97
$248.16
Beigene Ltd Adr Stock (BGNE) Company Profile
Name
Beigene Ltd Adr
Sector
Industry
Phone
13459494123
Address
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Compare BGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BGNE
Beigene Ltd Adr
|
184.71 | 19.68B | 3.32B | -860.46M | -1.04B | -8.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Beigene Ltd Adr Stock (BGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-24 | Resumed | Morgan Stanley | Overweight |
| Sep-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-06-24 | Resumed | JP Morgan | Overweight |
| Sep-12-23 | Initiated | Macquarie | Outperform |
| Aug-17-23 | Initiated | Jefferies | Buy |
| Jul-17-23 | Initiated | Citigroup | Buy |
| Jun-30-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-12-23 | Initiated | Daiwa Securities | Buy |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-09-22 | Resumed | JP Morgan | Overweight |
| Mar-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-07-22 | Initiated | Deutsche Bank | Buy |
| Oct-12-21 | Initiated | Bernstein | Outperform |
| Oct-06-21 | Upgrade | CLSA | Underperform → Buy |
| Mar-08-21 | Initiated | China Renaissance | Buy |
| Mar-01-21 | Downgrade | CLSA | Outperform → Underperform |
| Nov-09-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-06-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-06-20 | Downgrade | Piper Sandler | Neutral → Underweight |
| Jul-10-20 | Downgrade | CLSA | Buy → Outperform |
| Mar-13-20 | Upgrade | Macquarie | Underperform → Neutral |
| Feb-18-20 | Resumed | Goldman | Buy |
| Jan-17-20 | Upgrade | CLSA | Outperform → Buy |
| Jan-17-20 | Resumed | Morgan Stanley | Overweight |
| Dec-16-19 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-16-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Nov-19-19 | Downgrade | UBS | Buy → Neutral |
| Nov-13-19 | Downgrade | CLSA | Buy → Outperform |
| Nov-04-19 | Reiterated | Maxim Group | Buy |
| Jun-04-19 | Initiated | Bernstein | Outperform |
| May-10-19 | Upgrade | CLSA | Outperform → Buy |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Jan-04-19 | Downgrade | CLSA | Buy → Outperform |
| Nov-21-18 | Initiated | JP Morgan | Overweight |
| Sep-25-18 | Initiated | Leerink Partners | Outperform |
| May-17-18 | Reiterated | Maxim Group | Buy |
View All
Beigene Ltd Adr Stock (BGNE) Latest News
Beigene's global head of R&D sells $1.29m in shares - Investing.com India
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire Inc.
BeiGene stock soars to 52-week high of $258.66 amid robust growth - Investing.com India
BeiGene's president sells $12.5 million in company shares - Investing.com
Beigene's Wang Xiaodong sells $9.4 million in shares - Investing.com India
Beigene's Wang Xiaodong sells $9.4 million in shares By Investing.com - Investing.com South Africa
CCBI Adds BEIGENE's TP to $179 for Better Fundamentals This Yr - AASTOCKS.com
BEIGENE (06160.HK) Climbs 6% in Early Session, Expects to Achieve Positive Operating Income This Yr - AASTOCKS.com
Beigene director Wang Xiaodong sells $7.37 million in shares - Investing.com
HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com
(NASDAQ:BGNE) Stock Quotes, Forecast and News Summary - Benzinga
FDA approves BeiGene's TEVIMBRA for advanced gastric cancer treatment - Investing.com
With 45% institutional ownership, BeiGene, Ltd. (NASDAQ:BGNE) is a favorite amongst the big guns - Yahoo Finance
Weekly Upgrades and Downgrades - InvestorPlace
BeiGene shares reiterate Buy rating on robust oncology pipeline - Investing.com India
Beigene directors sell shares worth $194.2 million - Investing.com
Beigene president Wu Xiaobin reports $120,894 sale of economic interest By Investing.com - Investing.com South Africa
Beigene president Wu Xiaobin reports $120,894 sale of economic interest - Investing.com
Beigene sees $3.57 billion stock sale by Hillhouse Investment By Investing.com - Investing.com South Africa
Beigene sees $274 million stock sale by Hillhouse Investment By Investing.com - Investing.com
AGFA Gevaert NV (AGFB.BR) Stock Price, News & Analyst Forecast - eToro
Morgan Stanley increases BeiGene stock target on drug prospects - Investing.com
10 High Growth Healthcare Stocks to Invest in Now - Insider Monkey
Beigene's Wang Xiaodong sells shares worth $9.19 million - Investing.com
BeiGene stock outlook positive as Bernstein lifts price target, keeps Market Perform - Investing.com
China ADRs have increased to the largest share since late 2021 – GS - MSN
BeiGene settles patent litigation, extends BRUKINSA exclusivity - Investing.com
10 Biggest Biotechnology Companies - Investopedia
BeiGene announces name change to BeOne Medicines Ltd. - Investing.com
BeiGene shares lift on raised price target to $260 from $254 - Investing.com
UBS Raises BeiGene (BGNE.US) TP to US$289.7 as 3Q Results Beat - AASTOCKS.com
BeiGene shares fall despite better-than-expected Q3 results - Investing.com
BeiGene announces passing of board member Donald Glazer - Investing.com
BEIGENE Senior Staff Reportedly Investigated, but Not Related to Firm Operations - AASTOCKS.com
Beigene Ltd Adr Stock (BGNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.20%
2.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):